Related Experiment Video
Updated: May 8, 2026

Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
Published on: October 10, 2010
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Justin M Nussbaum1, Stephan Schilling, Holger Cynis
1Department of Biology, University of Virginia, Charlottesville, Virginia 22904, USA.
Abstract:
Extracellular plaques of amyloid-β and intraneuronal neurofibrillary tangles made from tau are the histopathological signatures of Alzheimer's disease. Plaques comprise amyloid-β fibrils that assemble from monomeric and oligomeric intermediates, and are prognostic indicators of Alzheimer's disease. Despite the importance of plaques to Alzheimer's disease, oligomers are considered to be the principal toxic forms of amyloid-β. Interestingly, many adverse responses to amyloid-β, such as cytotoxicity, microtubule loss, impaired memory and learning, and neuritic degeneration, are greatly amplified by tau expression. Amino-terminally truncated, pyroglutamylated (pE) forms of amyloid-β are strongly associated with Alzheimer's disease, are more toxic than amyloid-β, residues 1-42 (Aβ(1-42)) and Aβ(1-40), and have been proposed as initiators of Alzheimer's disease pathogenesis. Here we report a mechanism by which pE-Aβ may trigger Alzheimer's disease. Aβ(3(pE)-42) co-oligomerizes with excess Aβ(1-42) to form metastable low-n oligomers (LNOs) that are structurally distinct and far more cytotoxic to cultured neurons than comparable LNOs made from Aβ(1-42) alone. Tau is required for cytotoxicity, and LNOs comprising 5% Aβ(3(pE)-42) plus 95% Aβ(1-42) (5% pE-Aβ) seed new cytotoxic LNOs through multiple serial dilutions into Aβ(1-42) monomers in the absence of additional Aβ(3(pE)-42). LNOs isolated from human Alzheimer's disease brain contained Aβ(3(pE)-42), and enhanced Aβ(3(pE)-42) formation in mice triggered neuron loss and gliosis at 3 months, but not in a tau-null background. We conclude that Aβ(3(pE)-42) confers tau-dependent neuronal death and causes template-induced misfolding of Aβ(1-42) into structurally distinct LNOs that propagate by a prion-like mechanism. Our results raise the possibility that Aβ(3(pE)-42) acts similarly at a primary step in Alzheimer's disease pathogenesis.
Insights
Pyroglutamylated amyloid-beta (pE-Aβ) initiates Alzheimer's disease by forming toxic oligomers that depend on tau for neuronal death. These pE-Aβ oligomers propagate via a prion-like mechanism, driving disease pathogenesis.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) plaques and tau tangles.
- Oligomeric forms of Aβ are considered the most toxic species.
- Amino-terminally truncated, pyroglutamylated (pE) Aβ variants are more potent and implicated in initiating AD.
Purpose of the Study:
- To elucidate the mechanism by which pE-Aβ triggers Alzheimer's disease pathogenesis.
- To investigate the role of tau in pE-Aβ-induced neurotoxicity.
- To determine if pE-Aβ oligomers propagate via a self-seeding mechanism.
Main Methods:
- Co-oligomerization of Aβ(3(pE)-42) with Aβ(1-42) to form low-n oligomers (LNOs).
- Assessment of LNO cytotoxicity in cultured neurons, with and without tau.
- Serial dilution experiments to test LNO seeding and propagation.
- Analysis of LNOs from human AD brain and in a mouse model.
Main Results:
- Aβ(3(pE)-42) co-oligomerizes with Aβ(1-42) to form highly cytotoxic LNOs, dependent on tau.
- These pE-Aβ-containing LNOs can seed the formation of new toxic LNOs from Aβ(1-42) monomers.
- Aβ(3(pE)-42) was found in LNOs from human AD brains and induced neurotoxicity in mice.
- The observed neurotoxicity in mice was tau-dependent.
Conclusions:
- Aβ(3(pE)-42) drives tau-dependent neuronal death by forming distinct, cytotoxic LNOs.
- These toxic LNOs propagate through a prion-like, template-induced misfolding mechanism.
- Aβ(3(pE)-42) may represent a primary initiating factor in Alzheimer's disease pathogenesis.
Related Concept Videos
In-vitro Mutagenesis
In vitro Mutagenesis
TGF - β Signaling Pathway

